Becker's Healthcare September 26, 2024
Alexandra Murphy

The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades, Medscape reported Sept. 20.

Here are five things to know:

  1. KarXT is a coformulation of xanomeline and trospium chloride, designed to selectively activate muscarinic receptors in the brain, unlike traditional antipsychotics that primarily target dopamine receptors.
  2. The safety and effectiveness of the drug was assessed in phase 3 trials, which showed KarXT had a 9.6 point reduction in positive and negative syndrome scale scores compared to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
FDA’s views on AI are evolving
FDA Roundup: First 1-Year CGM, Lebrikizumab-lbkz for Atopic Dermatitis
Elon Musk’s Neuralink device Blindsight gets FDA breakthrough device designation
A Sea-Change is Coming in How Laboratory-Developed Tests are Regulated – Is your Lab Ready?

Share This Article